CoChat

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications

Ricciuti, Biagio, Leonardi, Giulia Costanza, Metro, Giulio, Grignani, Francesco, Paglialunga, Luca, Bellezza, Guido, Baglivo, Sara, Mencaroni, Clelia, Baldi, Alice, Zicari, Daniela, Crinò, Lucio · 2016 · Expert Review of Respiratory Medicine
Cited by 65

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Abstract

Lung cancer is the leading cause of cancer deaths worldwide, with non-small cell lung cancer (NSCLC) accounting for 80% of all lung cancers. Kirsten rat sarcoma viral oncogene homolog (KRAS) is one of the deadliest cancer-related proteins and plays a pivotal role in the most aggressive and lethal human cancers, including lung adenocarcinoma where it represents one of the most frequently mutated oncogene. Although therapeutic progresses have made an impact over the last decade, median survival for patients with advanced lung cancer remains disappointing, with a 5-year worldwide survival rate of <15%. For more than 20 years it has been recognized that constitutively active signaling downstream of KRAS is a fundamental driver of lung tumorigenesis. However, years of pursuit have failed to yield a drug that can safely curb KRAS activity; up to now no approved therapies exist for KRAS-mutant NSCLC. The aim of this review is to discuss the current knowledge of KRAS-mutated NSCLC, touching upon KRAS clinical relevance as a prognostic and predictive biomarker, with an emphasis on novel therapeutic approaches for the treatment of KRAS-variant NSCLC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1586/17476348.2016.1115349

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 21 references

Cited by

See all 65

Metadata

Authors
Ricciuti, B., Leonardi, G. C., Metro, G., Grignani, F., Paglialunga, L., Bellezza, G., Baglivo, S., Mencaroni, C., Baldi, A., Zicari, D., & Crinò, L.
Venue
Expert Review of Respiratory Medicine
Published
2015-11-17
Volume
10
Issue
1
Pages
53-68
ISSN
  • 1747-6348 (ISSN-L)
  • 1747-6356
OpenAlex
W2172948426
Cited by
65
References
21
FWCI
2.62
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. https://app.cochat.ai/papers/10.1586/17476348.2016.1115349
The paper
Ricciuti, B., Leonardi, G. C., Metro, G., Grignani, F., Paglialunga, L., Bellezza, G., Baglivo, S., Mencaroni, C., Baldi, A., Zicari, D., & Crinò, L. (2016). Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications. Expert Review of Respiratory Medicine. https://doi.org/10.1586/17476348.2016.1115349

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.